![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Prevalence and risk factors of preexisting TAMs in clinical trial participants and sustained viral suppression after switching to bictegravir/emtricitabine/tenofovir alafenamide
|
|
|
18th EACS 2021 Oct 27-30
K. Andreatta1, R. Acosta1, M.L. D'Antoni1, H. Liu1, S. Chang1, R. Martin1, S. Collins1, H. Martin1, K.L. White1
1Gilead Sciences, Inc., Foster City, United State
![1030211](../images/103021/103021-3/1030211.gif)
![1030212](../images/103021/103021-3/1030212.gif)
![1030213](../images/103021/103021-3/1030213.gif)
![1030214](../images/103021/103021-3/1030214.gif)
![1030215](../images/103021/103021-3/1030215.gif)
![1030216](../images/103021/103021-3/1030216.gif)
![1030217](../images/103021/103021-3/1030217.gif)
![1030218](../images/103021/103021-3/1030218.gif)
![1030219](../images/103021/103021-3/1030219.gif)
![10302110](../images/103021/103021-3/10302110.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|